These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2714933)

  • 1. Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors.
    Breitenecker G; Neunteufel W; Bieglmayer C; Kölbl H; Schieder K
    Int J Gynecol Pathol; 1989; 8(2):97-102. PubMed ID: 2714933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
    Neunteufel W; Breitenecker G
    Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
    Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
    Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):26-33. PubMed ID: 2227570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer.
    Picardo AL; Torres AJ; Maestro M; Ortega D; Garcia-Asenjo JA; Mugüerza JM; Hernando F; Diez M; Balibrea JL
    Cancer; 1994 May; 73(9):2305-11. PubMed ID: 8168034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
    Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
    Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors.
    Motoyama T; Watanabe H; Takeuchi S; Watanabe T; Gotoh S; Okazaki E
    Cancer; 1990 Dec; 66(12):2628-35. PubMed ID: 2174304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age.
    Var T; Tonguc EA; Ugur M; Altinbas S; Tokmak A
    Bratisl Lek Listy; 2012; 113(2):95-8. PubMed ID: 22394039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of tumor markers CA 15-3 and CEA in breast cancer].
    Buck I; Lindner C; Böge K; Kitschke HJ
    Arch Gynecol Obstet; 1989; 245(1-4):674-7. PubMed ID: 2802753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
    Avall Lundqvist E; Nordström L; Sjövall K; Eneroth P
    Eur J Gynaecol Oncol; 1989; 10(6):395-405. PubMed ID: 2627971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
    Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 125 as a marker in epithelial ovarian cancer: Alone and in comparison with CEA.
    Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH; Balar DB; Patel TB
    Indian J Cancer; 1987 Dec; 24(4):222-31. PubMed ID: 3505511
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
    Panza N; Pacilio G; Campanella L; Peluso G; Battista C; Amoriello A; Utech W; Vacca C; Lombardi G
    Cancer; 1988 Jan; 61(1):76-83. PubMed ID: 2446734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of carcinoma-associated antigen 494 in colorectal cancer tissue and in Patients' sera during metastatic disease.
    Lindhorst E
    Tumour Biol; 2000; 21(2):116-22. PubMed ID: 10686541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carcinoma with low malignant potential (borderline tumor) of the ovary: immunomorphology and clinical aspects].
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Arch Gynecol Obstet; 1989; 245(1-4):600-2. PubMed ID: 2679431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers in breast cancer: does CEA add to the detection by CA 15.3?
    Delarue JC; Mouriesse H; Dubois F; Friedman S; May-Levin F
    Breast Cancer Res Treat; 1988 Jul; 11(3):273-6. PubMed ID: 3167234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in gynecologic diseases].
    Geyer H; Kleine W
    Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.